Effect of 17 α-Hydroxyprogesterone Caproate on Glucose Intolerance in Pregnancy.

The article presents a study which examines the effects of 17αhydroxyprogesterone caproate treatment on maternal glucose testing and gestational diabetes mellitus (GDM) within body mass index (BMI) categories. The main outcomes of the study were an abnormal 1-hour 50-gram (g) glucose screen and GDM. The results demonstrate that those women receiving weekly intramuscular 17αhydroxyprogesterone caproate have abnormal glucose testing and GDM.